Wedbush Research Analysts Lower Earnings Estimates for CMPX

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at Wedbush decreased their Q3 2025 earnings per share estimates for Compass Therapeutics in a research report issued on Tuesday, April 1st. Wedbush analyst R. Driscoll now expects that the company will earn ($0.13) per share for the quarter, down from their prior forecast of ($0.10). Wedbush has a “Outperform” rating and a $8.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics’ Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.42 EPS.

A number of other equities research analysts have also weighed in on CMPX. HC Wainwright raised their price objective on shares of Compass Therapeutics from $10.00 to $24.00 and gave the company a “buy” rating in a report on Friday. Guggenheim reissued a “buy” rating and set a $12.00 target price on shares of Compass Therapeutics in a research report on Wednesday. Leerink Partners raised Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $6.00 in a report on Wednesday. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 1st. Finally, Piper Sandler started coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $13.38.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.46 on Friday. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a market capitalization of $201.89 million, a PE ratio of -3.95 and a beta of 1.40. The stock has a 50-day simple moving average of $2.76 and a 200-day simple moving average of $2.10.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Institutional Trading of Compass Therapeutics

Several hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC lifted its position in Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock valued at $25,000 after purchasing an additional 12,917 shares during the period. Independent Advisor Alliance acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets purchased a new stake in Compass Therapeutics during the fourth quarter worth about $27,000. Intech Investment Management LLC purchased a new stake in Compass Therapeutics during the third quarter worth about $30,000. Finally, Mariner LLC acquired a new position in Compass Therapeutics during the fourth quarter worth about $30,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.